Nédemax® Mese (Leucoselect®, Lymphaselect®, Bromelain) in the treatment of chronic venous disease: a multicenter, observational study

Albrigo, R.; Andreoni, Cinzia; Anello, Gaetano; Barzaghi, Elena; Bianchi, Daniele; Camassa, Nino; Carissimi, T; Collarino, Francesco; Cozzolino, Giuseppe; Cravero, Enzo; Cristiani, Alfonso; Corso, Antonella Del; Dibiase, Massimiliano; Cosmo, Incoronata Di; Ermirio, D.; Farina, Mário; Florio, Anna; Fornalè, Lorenzo; Franchini, Gianluigi; Franzoso, Massimo; Ferri, Maura; Gallinacci, E; Gazzetti, Marianna; Giacomelli, Elena; Giuliani, Nadia; Grimaldi, Giuseppe; Guida, C; Iurlaro, Vincenzo; Marcellino, M. G.; Mele, Rita; Mercandalli, Giulio; Mirabella, Domenico; Mondani, Paolo; Morozzo, G; Noce, L; Oberto, Sara; Paccasassi, Stefania; Pagano, Guerino; Pagliasso, Elisa; Palazzo, Annunziata; Palombi, M.; Palumbo, Francesco Paolo; Petracca, Giovanni; Pontello, Daniele; Puviani, Lorenza; Puzzo, A; Ragni, Elena; Simoncini, Fabio; Somigli, Lorenzo; Spina, Tommaso; Spinamano, Luca; Terreni, Angela; Tondo, Salvatore; Tonelli, Vincenzo; Tortora, A.; Giacomelli, Luca

doi:10.23736/s1593-232x.19.00437-5

Cited by 5 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A comparable pattern was observed for the severity of the disease and symptomatology. 174 Muir et al have investigated the clinical efficacy of Ginkgo biloba phytosome, in the treatment of Raynaud's phenomenon (RP). A painful condition characterized by episodic digital ischemia.…”

Section: Phytosomes and Cardiovascular Protectionmentioning

confidence: 99%

Phytosomes as Innovative Delivery Systems for Phytochemicals: A Comprehensive Review of Literature

Barani¹,

Sangiovanni²,

Angarano³

et al. 2021

IJN

109

View full text Add to dashboard Cite

Nowadays, medicinal herbs and their phytochemicals have emerged as a great therapeutic option for many disorders. However, poor bioavailability and selectivity might limit their clinical application. Therefore, bioavailability is considered a notable challenge to improve bio-efficacy in transporting dietary phytochemicals. Different methods have been proposed for generating effective carrier systems to enhance the bioavailability of phytochemicals. Among them, nano-vesicles have been introduced as promising candidates for the delivery of insoluble phytochemicals. Due to the easy preparation of the bilayer vesicles and their adaptability, they have been widely used and approved by the scientific literature. The first part of the review is focused on introducing phytosome technology as well as its applications, with emphasis on principles of formulations and characterization. The second part provides a wide overview of biological activities of commercial and non-commercial phytosomes, divided by systems and related pathologies. These results confirm the greater effectiveness of phytosomes, both in terms of biological activity or reduced dosage, highlighting curcumin and silymarin as the most formulated compounds. Finally, we describe the promising clinical and experimental findings regarding the applications of phytosomes. The conclusion of this study encourages the researchers to transfer their knowledge from laboratories to market, for a further development of these products.

show abstract

Section: Phytosomes and Cardiovascular Protectionmentioning

confidence: 99%

Phytosomes as Innovative Delivery Systems for Phytochemicals: A Comprehensive Review of Literature

Barani¹,

Sangiovanni²,

Angarano³

et al. 2021

IJN

109

View full text Add to dashboard Cite

show abstract

“…Significant reduction in malleolus circumference of both limbs was reported in all groups, but more evident in bromelain-OPC-coumarin plus compression stocking and monotherapy of bromelain-OPC-coumarin combination groups compared to the group which received only compression stocking. 39 Rutoside, alone, has also been studied extensively, for the treatment of venous insufficiency associated conditions. In a double-blind, randomized, placebo-controlled study, 40 patients with venous insufficiency were treated with hydroxyethyl rutoside (rutoside) and 20 received placebo for 4 weeks.…”

Section: Clinical Studies With Setmentioning

confidence: 99%

Systemic enzyme therapy in chronic venous disease: a review

2021

View full text Add to dashboard Cite

Chronic venous disease (CVD), a sequel of venous insufficiency, has great medical and socioeconomic impact. Varicose veins and venous ulcer are amongst its commonest manifestations. In CVD, incompetent valves, weakened vascular walls, venous hypertension and increased permeability of venous walls lead to the release of proinflammatory mediators like tumor necrosis factor (TNF)-α, interleukin (IL)-1β, reactive oxygen species (R.O.S.), and reactive nitrogen species (R.N.S.) in the venous milieu. Pharmacotherapy with nonsteroidal anti-inflammatory drugs (NSAIDs) is often used to relieve pain caused by venous disease. However, there is a need for therapies that target the microcirculatory disorders and act on chronic inflammatory processes. Systemic enzyme therapy (SET), with orally administered combination of proteolytic enzymes- trypsin, bromelain, and flavonoid rutoside, has been used since decades for their anti-inflammatory, analgesic, anti-edematous, antithrombotic and antioxidant properties. This review discusses the various relevant pharmacodynamic properties demonstrated by the ingredients, followed by clinical studies of SET, which have demonstrated benefit in both subjective and objective parameters. These studies indicate that SET has good efficacy, tolerability and holds great promise to improve the quality of life of a patient with CVD.

show abstract